Pure Global AI
NCT05983237Not yet recruiting

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

Phase Ib Study of Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma With Homologous Recombination (HR) Mutation ，a Single-center Open-label Exploratory Clinical Trial
Peking University Cancer Hospital & InstitutePhase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Melanoma
Drug/Device/Intervention
Fluzoparib Camrelizumab Temozolomide
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Peking University Cancer Hospital & Institute
Timeline & enrollment
Phase
Phase 1/2
Start date
Aug 31, 2023
End date
Dec 31, 2025
Enrollment
50 participants
Primary outcome

Objective Response Rate (ORR)

Summary

The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab
 and temozolomide works in treating patients with advanced, metastatic melanoma with the
 homologous recombination (HR) pathway gene mutation / alteration.

ICD-10 classifications
Malignant melanoma of skinMelanoma in situ, unspecifiedMelanoma in situMelanoma and other malignant neoplasms of skinMalignant neoplasm: Malignant melanoma of skin, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05983237
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05983237 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Peking University Cancer Hospital & Institute and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.